India Pharma Outlook Team | Monday, 02 March 2026
Eli Lilly is holding firm on premium pricing for its blockbuster innovator drug tirzepatide in India, even as a wave of cheaper generics from rival semaglutide looms just weeks away.
The company markets tirzepatide as Mounjaro for diabetes and weight loss, and through a partnership with Cipla as Yurpeak. Despite the upcoming competition, Eli Lilly sees clear separation between the premium branded segment and the generic one.
Winselow Tucker, president and general manager of Eli Lilly India: "We are an innovative company with an innovative product, and we price based on the value delivered to patients, physicians, and the healthcare system... There is room for both segments."
Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies
This stance comes right before Novo Nordisk's semaglutide—the active ingredient in Ozempic and Wegovy—loses patent protection in India on March 21, 2026. That opens the door for Indian giants like Sun Pharmaceuticals, Dr Reddy's Laboratories, Zydus Lifesciences, Natco Pharma, and others to flood the market with generics priced around INR 3,000–5,000 per month. That's roughly 50 percent less than current branded options, where Ozempic runs INR 8,800–11,175 and Wegovy INR 10,850–16,400 monthly.
Eli Lilly justifies the higher cost of Mounjaro—ranging from more than INR 13,000 to about INR 26,000 per monthly injection (four shots)—by pointing to tirzepatide's edge as the only dual GIP/GLP-1 agonist available. It delivers stronger results, with average weight loss of 20–22 kg and better glucose control compared to semaglutide's 16–18 kg for Wegovy. Flexible single-vial options help too: INR 3,281 for 2.5 mg and INR 4,101 for 5 mg.
Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries said, "As India's largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry."
Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future
Tirzepatide demand in India has exploded since launch. Mounjaro racked up about INR 720 crore in sales over its first 10 months through January 2026, with January alone hitting around INR 120 crore—making it the top-selling drug by monthly value in a market usually driven by volume. Add in Yurpeak's recent INR 33 crore contribution (launched about two months ago), and the pair is on pace to reach INR 3,500 crore by March 2027.
In contrast, Novo Nordisk's Ozempic and Wegovy trail far behind with just INR 8 crore and INR 72 crore in sales, respectively.
Eli Lilly plans to fuel further growth through disease awareness efforts, digital campaigns, and its expanding pipeline, including oral orforglipron and the Alzheimer's candidate donanemab. The company views India as a major strategic hub, with nearly 10% of its global workforce based there.
Vikrant Shrotriya, Managing Director, Novo Nordisk India said, "On pricing adjustments amid competition: "We realized just after a couple of months that for accessibility, we had to take a price cut," referring to Wegovy's up to 37% reduction to boost reach. He downplays patent expiry concerns, focusing on "quality, trust and affordability rather than on patents or competition in India."
As the GLP-1 and anti-obesity space heats up, Eli Lilly is betting that tirzepatide's proven superiority and innovation will keep patients and doctors choosing the premium option, even when more affordable generics arrive and boost overall access in India's booming cardiometabolic market.
